3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Peripheral
4
Lymphoma, T-Cell
4
Lymphoma, Large-Cell, Anaplastic
3
Recurrence
2
Multiple Myeloma
2
Lymphoma, Follicular
2
Immunoblastic Lymphadenopathy
2
Esophageal Squamous Cell Carcinoma
2
Adenocarcinoma Of Esophagus
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Enteropathy-Associated T-Cell Lymphoma
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
165
fludarabine phosphate
110
Peripheral Blood Stem Cell Transplantation
94
Mycophenolic Acid
88
Whole-Body Irradiation
81
Etoposide
81
Tacrolimus
73
Busulfan
68
Melphalan
67
Filgrastim
66
fludarabine
62
Radiotherapy
56
Doxorubicin
54
Cyclosporine
54
Rituximab
50
Brentuximab Vedotin
48
Antilymphocyte Serum
47
Granulocyte Colony-Stimulating Factor
42
Vinblastine
41
Methotrexate
38
Dacarbazine
37
Cytarabine
35
Gemcitabine
34
Nivolumab
30
Bleomycin
29
Carmustine
28
Vincristine
25
Prednisone
25
Sirolimus
24
Bendamustine Hydrochloride
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hodgkin Disease
×
10-propargyl-10-deazaaminopterin
×
Clear all
NCT01947140
2022-11-23
PDX+Romi
Columbia University
Phase 1/2
Completed
57 enrolled